Abstract
jats:titleAbstract</jats:title>jats:pOne of the biggest obstacles to drug development for the central nervous system (CNS) is the blood–brain barriers (BBBs). These consist of the vascular BBB, the choroid plexus (blood‐cerebrospinal fluid barrier), the tanycytic barrier at the circumventricular organs, and some specialized barriers, such as the blood–retinal barrier. Of these barriers, the vascular BBB is the most studied and most targeted for CNS drug delivery. An understanding of the comp